Quality of life (QoL) in patients (pts) with locally advanced or metastatic breast cancer (MBC) previously treated with anthracyclines and taxanes who received eribulin mesylate or capecitabine: A phase III, open-label, randomized study.

Authors

Javier Cortes

Vall d'Hebron University Hospital, Barcelona, Spain

Javier Cortes , Ahmad Awada , Peter Andrew Kaufman , Louise Yelle , Edith A. Perez , Galina Velikova , Jantien Wanders , Martin S. Olivo , Yi He , Corina Dutcus , W. Robert Simons , Christopher Twelves

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Sign-In

Similar Posters

insert_chart_outlined

Poster

2013 ASCO Annual Meeting

bookmark_border

A phase III, open-label, randomized study of eribulin mesylate versus capecitabine in patients with locally advanced or metastatic breast cancer (MBC) previously treated with anthracyclines and taxanes: Subgroup analyses.

First Author: Peter Andrew Kaufman

insert_chart_outlined

Poster

2018 ASCO Annual Meeting

bookmark_border

ATTAIN: Phase 3 study of etirinotecan pegol (EP) vs. treatment of physician's choice (TPC) in patients (pts) with metastatic breast cancer (MBC) who have stable brain metastases (BM) previously treated with an anthracycline, a taxane, and capecitabine (ATC).

First Author: Debu Tripathy

insert_chart_outlined

Poster

2017 ASCO Annual Meeting

bookmark_border

ATTAIN: Phase 3 study of etirinotecan pegol (EP) vs treatment of physician's choice (TPC) in patients (pts) with metastatic breast cancer (MBC) who have stable brain metastases (BM) previously treated with an anthracycline, a taxane, and capecitabine (ATC).

First Author: Debu Tripathy

insert_chart_outlined

Poster

2020 ASCO Virtual Scientific Program

bookmark_border

Randomized phase III trial of eribulin (E) versus standard weekly paclitaxel (P) as first- or second-line therapy for locally recurrent or metastatic breast cancer (MBC).

First Author: Minetta C. Liu